Longeveron (LGVN) Reports Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Longeveron Inc. announced additional new clinical and biomarker results from its Phase 2a CLEAR MIND trial of its investigational product Lomecel-B? for the treatment of mild Alzheimer?s disease. The.
ASD, a complex neurodevelopmental disorder, is known to be linked to altered brain development. However, precise markers that can accurately diagnose ASD at the individual level have been elusive.